Insmed Incorporated — FY 2011 Form 10-K
Business context and reporting period. This development-stage biopharmaceutical company reported for the year ended December 31, 2011. Its principal focus is ARIKACE, an inhaled liposomal amikacin candidate for serious lung infections, especially in cystic fibrosis (CF) and nontuberculous mycobacterial (NTM) disease. The company completed integration with Transave during 2011 and closed its Richmond, Virginia operations at year-end.
Financial performance and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $4.4 million | $6.9 million |
| Research and development expense | $27.9 million | $4.8 million |
| General and administrative expense | $12.2 million | $10.3 million |
| Operating loss | $61.7 million | $8.1 million |
| Net loss | $59.7 million | $6.4 million |
| Net loss attributable to common stockholders | $68.8 million, or $2.95 per share | $6.4 million, or $0.49 per share |
| Net cash used in operating activities | $30.2 million | $7.7 million |
Revenue fell $2.5 million, primarily because IPLEX expanded-access cost-recovery revenue declined $3.5 million; $1.0 million of CISPLATIN licensing fees partly offset the decrease. IPLEX inventory was exhausted at year-end, ending this program’s cost-recovery revenue. R&D increased substantially as ARIKACE clinical development and manufacturing ramped up. The annual common-stockholder loss includes a $26.0 million non-cash impairment charge and a $9.2 million non-cash beneficial-conversion charge related to Series B preferred stock.
Fourth-quarter 2011 revenue was $1.4 million, operating loss was $8.9 million, and net loss after tax was $8.2 million. The filing does not provide a clear standalone fourth-quarter cash-flow value.
At December 31, cash, cash equivalents, short-term investments and a certificate of deposit totaled $78.4 million; cash and short-term investments were $76.3 million. Working capital was $72.9 million, total assets $139.8 million, and stockholders’ equity $134.3 million. The company reported no long-term debt; capital-lease obligations totaled approximately $0.3 million. Operating-lease commitments were $4.5 million, with total contractual obligations of $4.8 million. Management said funds were sufficient for 2012, while warning that further financing may be needed.
Material developments, outlook and risks
- ARIKACE regulatory status: FDA clinical holds were imposed in August 2011 for CF and NTM programs following two lung tumors among 120 rats at the highest dose in a long-term inhalation study. The relevance to humans was unknown. The FDA lifted the NTM hold in January 2012, but required a Phase 2 adult trial; enrollment was expected to start mid-2012. The U.S. CF hold remained in place at filing, and Insmed submitted a complete response in February 2012. The FDA requested a nine-month dog inhalation toxicity study and further consideration of the CF population and risk-benefit profile.
- Development plans: Insmed expected to begin a roughly 300-patient European Phase 3 CF trial in the second quarter of 2012, comparing once-daily ARIKACE with twice-daily TOBI. The primary endpoint is change in lung function (FEV-1); time to pulmonary exacerbation is a key secondary endpoint. These were forward-looking plans, not completed milestones.
- Clinical evidence: Phase 2 CF studies reported lung-function and microbiological improvements, including sustained benefit in an open-label multi-cycle study. These results do not establish Phase 3 success or regulatory approval. ARIKACE had orphan designation for CF in the U.S. and EU; the NTM orphan-designation application required additional supporting data.
- Business and funding risks: Insmed had no material ongoing operating-revenue source after IPLEX supplies were depleted, expected continuing losses, and had no committed source of additional capital. Failure to raise funds could force reductions or delays in development. The company also relied on third parties for ARIKACE manufacturing and the investigational nebulizer, and commercial supply agreements had not been established.
- Other programs and unusual items: IPLEX was no longer a development priority; the company intended to seek licensing partners and lacked in-house manufacturing capability. The Richmond facility closure generated a $1.2 million charge. A Delaware appraisal action and an IPLEX-related lawsuit remained unresolved; management said potential losses could not be estimated. The company recorded a $26.0 million impairment of acquired in-process R&D and goodwill following the clinical holds.
- Financial reporting: Ernst & Young issued an unqualified opinion on the financial statements and internal controls. Management also concluded disclosure controls and internal control over financial reporting were effective at year-end.
Most important facts for investors to verify
- Subsequent FDA actions on the U.S. CF hold, the dog toxicity study, and the timing and results of the European Phase 3 and U.S. NTM Phase 2 trials.
- Cash use and financing runway relative to ARIKACE trial, manufacturing, and commercialization costs; the company’s 2012 funding statement is not a longer-term runway assurance.
- Whether clinical findings translate into confirmatory efficacy and acceptable safety, particularly given the rat tumor signal and unresolved human relevance.
- Potential dilution, including shares issuable to former Transave stockholders and outstanding options, warrants, and restricted stock units.
- Outcomes and financial exposure from the appraisal proceeding and remaining IPLEX-related litigation, as well as the ability to sublet the vacant Richmond facility.